Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:28:06 EDT Thu 18 Sep 2025
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q6.7113.37·113.391.1113.38+1.121.01,769.0198,46325,169111.26  113.565  111.26121.82  81.829814:08:01Sep 0415 min RT 2¢

Recent Trades - Last 10 of 25169
Time ETExPriceChangeVolume
14:08:11Q113.381.122
14:08:11Q113.381.1212
14:08:11Q113.381.1235
14:08:11Q113.381.123
14:08:11Q113.381.1210
14:08:11Q113.381.126
14:08:09Q113.36591.10591
14:08:07Q113.401.1415
14:08:06Q113.391.1311
14:08:06Q113.401.14100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-09-04 14:15U:GILDNews ReleaseGilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
2025-09-04 08:30U:GILDNews ReleaseGilead Sciences Launches Choose U(TM) Campaign Spotlighting the Inspiring Experiences of People Living with HIV
2025-09-03 11:30U:GILDNews ReleaseGilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
2025-08-26 03:00U:GILDNews ReleaseEuropean Commission Authorizes Twice-Yearly Yeytuo(TM) (Lenacapavir) for HIV Prevention
2025-08-21 08:30U:GILDNews ReleaseKite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
2025-08-20 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2025-08-07 16:02U:GILDNews ReleaseGilead Sciences Announces Second Quarter 2025 Financial Results
2025-07-25 03:00U:GILDNews ReleaseGilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
2025-07-24 16:05U:GILDNews ReleaseGilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
2025-07-23 10:15U:GILDNews ReleaseLooking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic
2025-07-14 09:30U:GILDNews ReleaseGilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo(TM)) for HIV Prevention at IAS 2025
2025-07-09 08:00U:GILDNews ReleaseGilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
2025-06-25 07:00U:GILDNews ReleaseGilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
2025-06-24 09:25U:GILDNews ReleaseGilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion
2025-06-18 14:49U:GILDNews ReleaseYeztugo(TM) (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
2025-06-05 09:20U:GILDNews ReleaseGilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
2025-06-01 08:00U:GILDNews ReleaseKite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta(TM) in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
2025-05-31 08:00U:GILDNews ReleaseTrodelvy(TM) Plus Keytruda(TM) Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
2025-05-30 09:35U:GILDNews ReleaseGilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden
2025-05-23 08:30U:GILDNews ReleaseASCENT-03: Trodelvy(TM) Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors